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Abstract Acute ischemic stroke, the most frequent cause of
Transl. Stroke Res. (2016) 7:54–69
DOI 10.1007/s12975-015-0440-8
permanent disability in adults worldwide, results from tran-
sient or permanent reduction in regional cerebral blood flow
and involves oxidative stress and inflammation. Despite the
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success of experimental animal models of stroke in identifying
anti-inflammatory/neuroprotective compounds, translation of
these putative neuroprotectants to human clinical trials has
failed to produce a positive outcome. Tissue injury and stress
activate endogenous mechanisms which function to restore
homeostatic balance and prevent further damage by upregu-
lating the synthesis of lipid signaling molecules, including N-
palmitoylethanolamine (PEA or palmitoylethanolamide).
PEA exerts neuroprotection and reduces inflammatory sec-
ondary events associated with brain ischemia reperfusion in-
jury (middle cerebral artery occlusion (MCAo)). Here, we
examined the neuroprotect ive potent ia l of a co-
ultramicronized composite containing PEA and the antioxi-
dant flavonoid luteolin (10:1 by mass), nominated co-
ultraPEALut. The study consisted of two arms. In the first,
rats subjected to MCAo and treated with co-ultraPEALut
post-ischemia showed reduced edema and brain infract vol-
ume, improved neurobehavioral functions, and reduced ex-
pression of pro-inflammatory markers and astrocyte markers.
In the second arm, a cohort of 250 stroke patients undergoing
neurorehabilitation on either an inpatient or outpatient basis
were treated for 60 days with a pharmaceutical preparation of
co-ultraPEALut (Glialia®). At baseline and after 30 days of
treatment, all patients underwent a battery of evaluations to
assess neurological status, impairment of cognitive abilities,
the degree of spasticity, pain, and independence in daily living
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Introduction
Stroke is the second leading cause of death and the preeminent
cause of neurological disability worldwide [1–3]. Ischemic
stroke results from the sudden decrease or loss of blood circu-
lation to an area of the brain, resulting in a corresponding loss
of neurological function. Deficits can include partial paralysis,
difficulties with memory, thinking, language, and movement.
While the prompt restoration of blood flow to the ischemic
tissue is the current strategy of choice in clinical stroke treat-
ment, this can cause additional damage and exacerbate
neurocognitive deficits. Inflammation is a key feature of cere-
bral ischemia [4, 5] with major immune system players, name-
ly microglia [6, 7] and mast cells [8, 9] acting as early re-
sponders. This response leads to the production of pro-
inflammatory mediators and infiltration of other inflammatory
cell populations (e.g., neutrophils, T cell subsets, monocyte/
macrophages) into the ischemic brain tissue. Additional, late-
phase responders include reactive astrocytes and the resulting
glial scar which forms in the boundary zone of the ischemic
core and may play a critical role, both in detrimental and
beneficial terms [10].
Experimental animal models of stroke enabled the identi-
fication of a wide array of anti-inflammatory/neuroprotective
compounds, including anti-epileptics, inhibitors of inducible
nitric oxide synthase and kinases, minocycline, antioxidants,
and polyphenols [11–15]. Some of these putative
neuroprotectants have been tested in human clinical trials,
but they have yielded little positive outcome [3, 16]. Never-
theless, neuroprotection studies utilizing animal models still
provide useful insights into strategies for limiting stroke se-
verity as they continue to offer translational potential for im-
proving future stroke outcome [3, 17]. The failure of therapies
targeted only to neuronal cell protection may be attributable,
in part, to a lack of concomitant protection of cerebral blood
vessels from secondary injury by inflammation and reactive
oxygen species/reactive nitrogen species. Although anti-
inflammatory approaches have proven successful in animal
models of stroke [18, 19], attempts to translate this into clin-
ical application have fallen short of expectations [20, 21].
In response to tissue injury and stress, the body is known to
respond by producingmolecules Bon demand^which function to
restore homeostatic balance and prevent further damage [22].
Among these is a class of lipid signaling molecules, the N-
acylethanolamines (NAEs) [23, 24]. One NAE, in particular N-
palmitoylethanolamine (PEA or palmitoylethanolamide), is
surrounded by a large number of observations supporting its role
in maintaining cellular homeostasis by acting as a mediator of
resolution of inflammatory processes [25, 26]. These past years
have witnessed a continually growing number of studies
confirming the anti-neuroinflammatory and neuroprotective ac-
tions of PEA [27–30]. Interestingly, several recent studies have
shown that a co-ultramicronized PEA/luteolin composite (co-
ultraPEALut, 10:1 mass ratio) is more efficacious than PEA
alone [31, 32], including animal models of spinal cord injury
[33] and traumatic brain injury [34].
Based on the above observations, we carried out a two-part
study with co-ultraPEALut in cerebral ischemia. In the first
part of the study, we analyzed the neuroprotective and anti-
inflammatory properties of co-ultraPEALut in a rat model of
middle cerebral artery occlusion (MCAo), while in the second
part, the effects of co-ultraPEALut (Glialia®) were assessed in
stroke patients undergoing rehabilitation therapy. We chose to
conduct the study in subacute-phase stroke patients, given that
even at this stage, certain characteristic pathological features,
in particular neuro-inflammatory processes, are still active and
able to cause continued neuronal cell damage. Moreover,
many patients with ischemic stroke, despite optimal medical
treatment received during the acute phase, often fail to recover
(or only partially), leading to persistent disability requiring
rehabilitation. As Glialia® is already a marketed product, we
investigated whether treatment with Glialia®, carried out si-
multaneously with rehabilitation therapy, can bring about a
better functional recovery in stroke patients in the subacute
phase over a prolonged time frame.
Materials and Methods
Middle Cerebral Artery Occlusion
Male Wistar rats (Harlan, Italy) weighing 270–290 g were
used. Animals were housed in groups of three and kept on a
12-h light/dark cycle, under standardized temperature, humid-
ity, and light conditions with free access to food and water.
Animal care and use followed directives of the Council of the
European Community (86/609/EC). All efforts were made to
minimize animal suffering and to reduce the number of ani-
mals used. Focal cerebral ischemia was induced by transient
MCAo in the right hemisphere. The rats were anesthetized
with 5.0 % isoflurane (Baxter International) and spontaneous-
ly inhaled 1.0–2.0 % isoflurane in air by the use of a mask.
Body core temperature was maintained at 37 °Cwith a heating
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activities. All indices showed statistically significant gains at
study end. Despite its observational nature, this represents the
first description of co-ultraPEALut administration to human
stroke patients and clinical improvement not otherwise ex-
pected from spontaneous recovery. Further, controlled trials
are warranted to confirm the utility of co-ultraPEALut to im-
prove clinical outcome in human stroke.
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pad and was monitored via an intrarectal type T thermocouple
(Harvard, Kent, UK). The rats were placed in a stereotaxic
system (Kopf). Middle cerebral carotid artery (MCA) occlu-
sion was performed by inserting a 4-0 nylon monofilament
(Ethilon; Johnson & Johnson, Somerville, NJ, USA), pre-
coated with silicone (Xantopren; Heraeus Kulzer, Germany)
and mixed with a hardener (Omnident, Germany), via the
external carotid artery into the internal carotid artery to block
the MCA, as originally described by Longa et al. [35] and
modified by Melani et al. [36]. Sham rats were subjected to
the same surgical procedure, and the filament was inserted
into the internal carotid artery and immediately withdrawn.
At the end of the surgical procedure, anesthesia was
discontinued and the animals were returned to a prone posi-
tion. Recovery from anesthesia took 15 min; animals were
then allowed free access to food and water.
Regional cerebral blood flow (rCBF) was monitored by
laser Doppler flowmetry (PeriFlux System 5000; Perimed
AB, Stockholm, Sweden) with the use of a flexible probe over
the skull as described earlier [37]. The rats that did not show a
CBF reduction of at least 70 % were excluded from subse-
quent experiments. Cranial temperature was maintained at
36.8–37.5 °C with a heating pad. Some physiologic parame-
ters including cranial temperature, arterial pH, PaCO2, PaO2,
and glucose were measured in six additional rats. Arterial
blood samples were taken before ischemia (baseline), during
ischemia, and after ischemia for gases and plasma glucose
measurements (Table 1).
Animal Groups and Treatments
The rats were randomly allocated to the following groups:
– Ischemia/reperfusion+ vehicle: the rats (n=20) were sub-
jected to MCAo (2 h) followed by 24 h reperfusion [38].
Carboxymethyl cellulose in saline (1.5 %, w/v) was ad-
ministered (os) 1 h after ischemia and 6 h after reperfu-
sion, and the rats were sacrificed 24 h later for evaluation
of histological damage (n=10) andWestern blot (n=10);
– Ischemia/reperfusion+ co-ultraPEALut: the rats (n=20)
were subjected to surgical procedures as described above.
Co-ultraPEALut (1 mg/kg in 1.5 % carboxymethyl cellu-
lose, os) was administered (os) 1 h after ischemia and 6 h
after reperfusion, and the rats were sacrificed 24 h later
for evaluation of histological damage (n=10) and West-
ern blot (n=10);
– Sham+ vehicle: the rats (n=20) were subjected to identi-
cal surgical procedures except for MCA occlusion and
were kept under anesthesia for the duration of the exper-
iment. The animals were treated (os) with 1.5 % (w/v)
carboxymethyl cellulose in saline at the same time point
as the MCAo group and sacrificed 24 h later for evalua-
tion of histological damage (n=10) and Western blot
(n=10);
– Sham + co-ultraPEALut: the rats (n= 20) identical to
sham-operated rats except for administration of co-
ultraPEALut (1 mg/kg in 15 % carboxymethyl cellulose,
os) 1 h after ischemia and 6 h after reperfusion were
sacrificed 24 h later for evaluation of histological damage
(n=10) and Western blot (n=10).
In a separate set of experiments, 10 animals from each
group were observed until 24 h after MCAo to evaluate motor
behavior, perform neurological testing, and evaluate infarct
damage (Table 2). The dose (1 mg/kg) of co-ultraPEALut,
administration route (os), and vehicle used were based on
our previous study [39].
Motor Behavior
About 1 h after MCAo, the rats showed spontaneous turning
behavior that was evaluated every 15 min for 3–4 h post-
MCAo, as described by Melani et al. [40]. Motor activity
was assessed in sham-operated and vehicle- and drug-treated
rats. After being placed in a round cage, the rat began rapid
unidirectional walking along the perimeter of the cage and to
chase its tail. The number of complete rotations was recorded
manually. Five separate counting periods of 3 min each, sep-
arated by 15-min intervals, were made. Values are reported as
mean rotation number/h during the five counting periods. The
same rats were also evaluated after awakening and 24 h later
for failure to extend fully the left forepaw and for contralateral
turning when pulled by the tail. Under this condition, all the
rats showed a clear circling to the left side.
Neurological Scoring
Neurological evaluation of motor sensory functions was car-
ried out prior to and 24 h after MCAo by an examiner blinded
to the procedure, always between 10:00 a.m. and 11:00 a.m. to
exclude behavioral changes based on circadian rhythm. The
neurological examination consisted of six tests [41]: (i)
Table 1 Physiological
parameters, mean ± SD (n= 8) Time point Temperature (°C) pH PaCO2 (mmHg) PaO2 (mmHg) Glucose (mmol/l)
Baseline 37.2 ± 0.3 37.32 ± 0.2 38.2 ± 3.9 104.5 ± 10.9 4.31 ± 0.31
During ischemia 37.0 ± 0.2 37.36 ± 0.3 38.5 ± 5.1 103.2 ± 8.1 4.25 ± 0.22
After ischemia 36.8 ± 0.3 37.33 ± 0.1 38.3 ± 4.2 102.9 ± 9.9 4.27 ± 0.19
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spontaneous activity, (ii) symmetry in limb movements, (iii)
forepaw outstretching, (iv) climbing, (v) body proprioception,
and (vi) response to vibrissae touch. The six test scores were
summed to generate an assigned final score, which ranged
from a minimum of 3 to a maximum of 18.
Histological Evaluation of Infarct Damage
After evaluation of motor behavior and neurological deficit
24 h post-MCAo, the vehicle-treated (n = 10), co-
ultraPEALut-treated (n=10), and sham-operated rats (n=10)
were randomly selected and analyzed for ischemic damage
using published histological methods [36]. The rats were anes-
thetized and sacrificed by decapitation. The brains were rap-
idly removed and fixed with Carnoy’s solution (6:3:1 absolute
ethanol, chloroform, and glacial acetic acid) and then embed-
ded in paraffin after dehydration in graded series of ethanol
and xylol. Coronal sections (7–8 μm) were collected at 1-mm
intervals at eight different levels through the striatum (from +
2.2 Bregma to −4.8 Bregma, corresponding to the ischemic
area) and were stained with acetate cresyl violet (1 %) or
hematoxylin and eosin (H&E). The lesioned area was viewed
under light microscopy (Axiostar Plus equipped with
AxioCam MRc, Zeiss) as a pale zone lacking acetate cresyl
violet staining, a refection of the extent of unlabeled necrotic
neurons 24 h after MCAo [41]. The specific regions included
the cortical areas and hippocampus. In each region, the degree
of neuronal cell injury was assessed according to an incremen-
tal 5-point scale: 0 is normal, 1 denotes 10 % selective neuro-
nal injury, 2 denotes 10 to 50 % neuronal injury, 3 denotes
50 % neuronal injury, and 4 indicates confluent areas of pan-
necrosis as previously described [42].
Tissue damage was not found in either sham-operated rats
or the hemisphere contralateral to the ischemic side. Ischemic
tissue damage was clearly seen in the vascular territory sup-
plied by the MCA, i.e., the sensorimotor cortex and striatum.
The pallid area was measured by utilizing an image analysis
system (Image-Pro Plus; Image & Computer, Milan, Italy).
Striatal and cortical damage was calculated in cubic millime-
ters. All histological studies were performed in a blinded
fashion.
Quantification of Infarct Volume
The rats were anesthetized with ketamine and decapitated, and
the brains were carefully removed and cut into five coronal
slices of 2 mm in thickness. Slices were incubated in a 2 %
solution of 2,3,5-triphenyltetrazolium chloride (TTC) at 37 °C
for 30 min and immersion fixed in 10 % buffered formalin
solution. TTC stains viable brain tissue red, while infracted
tissue remains unstained [43]. For quantification of infracted
area and volumes, the brain slices were photographed using a
digital camera (Canon 4×; Canon Inc., China) and image anal-
ysis was performed on a personal computer with ImageJ for
Windows [44]. To compensate for the effect of brain edema,
the corrected infarct area equals the left hemisphere area mi-
nus (right hemisphere area minus infarct area) [45]. The
corrected total infarct volume was calculated by summing
the infarct area in each slice and multiplying by slice thickness
(2 mm).
Immunohistochemical Localization of Chymase, Tryptase,
and Glial Fibrillary Acidic Protein
Twenty-four hours after ischemia, tissues were fixed in 10 %
(w/v) phosphate-buffered formaldehyde and 7-μm sections
were prepared from paraffin-embedded tissues. After
deparaffinization, endogenous peroxidase was quenched with
0.3 % (v/v) hydrogen peroxide in 60 % (v/v) methanol for
30 min. The sections were permeabilized with 0.1 % (w/v)
Triton X-100 in phosphate-buffered saline (PBS) for 20 min.
Nonspecific adsorption was minimized by incubation in 2 %
(v/v) normal goat serum in PBS for 20min. Endogenous biotin
or avidin binding sites were blocked by sequential incubation
for 15 min with biotin and avidin, respectively. Sections were
then incubated overnight at room temperature with one of the
following primary antibodies: anti-chymase rabbit polyclonal
antibody (1:1000 in PBS), anti-tryptase rabbit polyclonal an-
tibody (1:1000 in PBS), or anti-glial fibrillary acidic protein
(GFAP) rabbit polyclonal antibody (1:100 in PBS) (Santa
Cruz, DBA, Milan, Italy). Sections were then washed with
PBS and incubated with a biotin-conjugated goat anti-rabbit
IgG and avidin–biotin–peroxidase complex (Vector
Table 2 Effect of co-
ultraPEALut (1 mg/kg, os, 1 h
after ischemia and 6 h after
reperfusion) on neurological
score and ischemic brain damage
evaluated 24 h after transient
MCAo
Treatment Neurological score Cortical damage (mm3) Striatal damage (mm3)
Vehicle 7.57 ± 0.21* 57.26± 2.33§§ 24.28 ± 2.37§
Co-ultraPEALut 9.13 ± 0.23# 37.72± 1.26 12.23 ± 2.1
Sham operated 17.5 ± 0.15 0 0
Data are the mean ± SD of n of rats (neurological score and brain damage, n= 10). The volume of the ipsilateral
hemisphere was as follows (mean ± SD): 127.75 ± 3.59 mm3 in co-ultraPEALut-treated rats. One-way ANOVA
followed by Bonferroni post hoc test was performed for neurological score
*p < 0.001, versus sham-operated rats; # p < 0.05, versus MCAo + vehicle (cortical and striatal damage was
analyzed using unpaired Student’s t test); § p< 0.05; §§ p < 0.01, versus co-ultraPEALut-treated rats
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Laboratories, DBA). No immunostaining was observed when
either the primary or secondary antibody was omitted. Images
captured (n=5 photos from each sample collected from all rats
in each experimental group) were quantitatively assessed for a
difference in immunoreactivity by computer-assisted color
image analysis (Leica QWin V3, Cambridge, UK). All analy-
ses were carried out by an investigator blinded to the treat-
ment. The number of GFAP-positive cells was acquired in
three defined brain regions: (i) a cortical infarct border zone
(IBZ), defined by the middle of the tangent to the cortical
lesion; (ii) an ipsilateral cortical remote zone (RZ), adjacent
to the interhemispheric gap; and (iii) a control region within
the contralateral hemisphere (CH) cortex equivalent to the
location of the IBZ. The number of GFAP-positive cells was
counted in three sections per animal and presented as the
number of positive cells per high-power field.
Western Blot Analysis
Cytosolic extracts were prepared with slight modifications.
Briefly, brain tissues from each rat were suspended in extrac-
tion buffer A containing 10 mM HEPES, 10 mM KCl,
0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol,
0.5 mM phenylmethylsulfonyl fluoride, 3 μg/ml pepstatin A,
2 μg/ml leupeptin, 15 μg/ml trypsin inhibitor, and 40 μM
benzamidine; homogenized at the highest setting for 2 min,
and centrifuged at 13,000g for 3 min at 4 °C. Supernatants that
represented the cytosolic fraction were retained and stored at
−80 °C until being used. Equivalent amounts of protein for
each sample were loaded per lane and electrophoretically sep-
arated using 10 % denaturing polyacrylamide gel electropho-
resis (PAGE) (SDS-PAGE). The filters were blocked with 1×
Tris-buffered saline (pH 7.5) and 5 % (w/v) nonfat dried milk
for 1 h at room temperature and subsequently probed with the
following primary antibodies: rabbit polyclonal anti-GFAP
(1:2000), anti-brain-derived neurotrophic factor (BDNF)
(1:1000; Santa Cruz Biotechnology), or anti-glial cell line-
derived neurotrophic factor (GDNF) (1:1000; Santa Cruz Bio-
technology), in 1× PBS, 5 % (w/v) nonfat dried milk, and
0.1 % Tween-2 at 4 °C overnight. Membranes were incubated
with peroxidase-conjugated bovine anti-mouse IgG secondary
antibody or peroxidase-conjugated goat anti-rabbit IgG
(1:2000; Jackson ImmunoResearch, West Grove, PA, USA)
for 1 h at room temperature. To control for protein loading, the
blots were stripped by agitation with 3 % glycine (pH 2) and
blocked in 1× PBS/5 % (w/v) nonfat dried milk for 1 h at
room temperature and then probed for 2 h at room temperature
with anti-β-actin antibody (Sigma-Aldrich). Relative expres-
sion of the protein bands was quantified by densitometric
scanning of the X-ray films with a GS-700 Imaging Densi-
tometer (Bio-Rad Laboratories) and a computer program (Mo-
lecular Analyst, IBM) and standardized for densitometric
analysis to β-actin levels.
Materials
Unless otherwise stated, all compounds were obtained from
Sigma-Aldrich Company Ltd. (Milan, Italy). All other
chemicals were of the highest commercial grade available.
All stock solutions were prepared in non-pyrogenic saline
(0.9 % NaCl; Baxter, Italy). Co-ultraPEALut was kindly sup-
plied by the Epitech Group (Saccolongo (PD), Italy). The
methodology underlying its preparation has been described
previously [33].
Assessment of Co-ultraPEALut in Stroke Patients
An observational study to evaluate the effects of co-ultraPEALut
(Glialia®) administration in stroke patients was carried out be-
tween April 2013 and June 2014, involving 37 neuromotor reha-
bilitation facilities throughout Italy. The patients selected had ex-
perienced a first ischemic stroke, were clinically stabilized, and
underwent rehabilitative therapy. Individuals with previous hos-
pitalizations for stroke and with hemorrhagic stroke were exclud-
ed. Of the 267 patients initially enrolled, 250 completed the study.
Seventeen patients were excluded from statistical evaluation for
the following reasons: bilateral stroke (4), no stroke at first event
(3), ischemic event occurred ≥18 months before the start of the
study (7), and inadequate information about ischemic event (3).
Eighty-four percent of patients were undergoing rehabilitative
treatment in inpatient centers and the remaining 16 % on an
outpatient basis. Table 3 summarizes the patient demographics,
while the location and type of stroke injury are collated in Table 4.
Therapy with Glialia® commenced at a median time of
18 days after the onset of the acute phase of stroke for inpa-
tients and after a median time of 104 days for patients under-
going rehabilitation on an outpatient basis. Written informed
consent was obtained from each patient or responsible family
member prior to the beginning of the study. All patients were
administered Glialia® (composed of co-ultramicronized
700 mg PEA and 70 mg luteolin, in microgranular form)
sublingually, twice daily (every 12 h) for 60 days in associa-
tion with the specific therapy (e.g., thrombolytics, aspirin, and
anticoagulants) normally administered and/or with drugs pre-
scribed for comorbidities, where present in the patient.
All patients underwent the following evaluations at base-
line (T0) and after 30 days (T30) of treatment: (i) stroke se-
verity by the Canadian Neurological Scale (CNS) [46], a tool
used to assess and monitor the neurological status of patients
with stroke; (ii) impairment of cognitive abilities by the Mini
Mental State Examination (MMSE) [47] adjusted for age and
educational level; (iii) degree of spasticity, by means of the
Ashworth Scale; (iv) pain, by the Numeric Rating Scale
(NRS), a scale of 0 to 10 points with 0 being no pain at all
and 10 being the worst pain imaginable; and (v) independence
in activities of daily living by the Barthel Index, which scales
functional capacity in terms of patient self-care [48].
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Evaluation of the degree of autonomy and/or dependence of
the patient from help, both physical and verbal, in carrying out
daily living activities was performed also at the 60th day,
concurrently with treatment end. During the period of rehabil-
itation therapy, patients were subjected to routine blood chem-
istry and hematology analyses and monitored for the possible
occurrence of adverse events.
Statistical Analysis
Preclinical Data
Statistically significant differences in neurological score were
evaluated by one-way ANOVA, followed by the Newman–
Keuls multiple comparison test. Statistically significant differ-
ences in the volume of brain ischemic damage were evaluated
using unpaired Student’s t test. The results were analyzed by
one-way ANOVA followed by the Bonferroni post hoc test for
multiple comparisons in neurological score. All values are
expressed as mean ±SD. A P value of less than 0.05 was
considered significant.
Clinical Data
To evaluate changes of means in time, the generalized linear
mixed model (GLMM) with SAS 9.2 was used. Variables
such as gender, age, and hospitalization type were included
in the model as covariates. The Bonferroni–Holm correction
for multiple comparisons was adopted for the CNS evaluation.
Results
Physiologic Parameters and rCBF
The changes of physiological parameters are shown in
Table 1. No statistical significance among different time
points for any of these parameters was noted. All physiolog-
ical parameters were within the normal range for the experi-
mental process. There was no significant difference in rCBF
between the control and treated group at the corresponding
time points (Fig. 1). Monitoring of rCBF showed successful
MCAo.
Neuroprotective Effects of Co-ultraPEALut on Turning
Behavior, Neurological Deficit, and Ischemic Brain
Damage in MCAo Rats
Turning behavior after permanent intraluminal MCAo is a
precocious index of neurological deficit and neuronal cell
damage [40, 41]. One hour after MCAo, the rats engaged in
turning behavior towards the side contralateral to the ischemic
hemisphere. This acute behavioral response lasted several
hours and was no longer evident 24 h after ischemia. Co-
ultraPEALut, administered orally, blocked this acute behav-
ioral response. Turning behavior, expressed as mean rotations
per hour, was 788±133 in MCAo vehicle-treated rats (n=10)
and 138±42 (n=10) in co-ultraPEALut-treated rats (mean
±SD). This effect of co-ultraPEALut was statistically signifi-
cant (unpaired Student’s t test: p<0.001 vs. vehicle-treated
rats). Sham-operated rats did not show any turning behavior.
Neurological deficit and ischemic striatal and cortical dam-
age ofMCAo vehicle-treated,MCAo co-ultraPEALut-treated,
and sham-operated rats were evaluated after 24 h (Table 2).
Co-ultraPEALut significantly improved MCAo-induced neu-
rological deficit in comparison to vehicle-treated rats and re-
duced both cortical and striatal damages in comparison to
vehicle-treated rats. No damage was found in the sham-
operated rats or in the hemisphere contralateral to the ischemic
side.
Effect of Co-ultraPEALut on Infarct Area
and Morphological Changes
Twenty-two hours after ischemia/reperfusion, the rats devel-
oped infarcts affecting the cortex and striatum (Fig. 2a). The
co-ultraPEALut treatment group (n=10) (Fig. 2b) had a sig-
nificantly smaller infarct area (n=10) (Fig. 2c) 24 h post-
MCAo compared with the control (n=10) (Fig. 2a). H&E






Mean ± SD 71.4 ± 12.4
Range 31–100
Inpatient, % (n) 84 (210)
Outpatient, % (n) 16 (40)
Table 4 Location and









Diffuse of injury 62.0
Internal capsule 26.6
External capsule 11.4
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in the sham group (data not shown), whereas 24 h after reper-
fusion, the brain sections from ischemic rats showed a paucity
of intact neurons in those areas (Fig. 2d (D1); see histological
score H) and the presence of multiple vacuolated interspaces
(Fig. 2d (D1); see histological score H). In contrast, the cor-
responding areas in the co-ultraPEALut group displayed
Fig. 2 Co-ultraPEALut reduces infarct area and histological damage in a
rat MCAomodel. Co-ultraPEALut (1 mg/kg) was administered orally 1 h
after ischemia and 6 h post-reperfusion. TTC staining of coronal brain
sections 24 h after MCAo. Infarcted brain tissue appears unstained (a),
while co-ultraPEALut treatment (b) significantly reduced infarct area (c).
H&E staining of MCAo tissue shows a loss of neurons and the presence
of multiple vacuolated interspaces (d, D1), which were significantly
ameliorated in co-ultraPEALut-treated animals (e, E1). Moreover,
damage to CA1 hippocampal neurons following ischemia/reperfusion
(f, F1) was significantly attenuated by co-ultraPEALut (g, G1). This
figure is representative of at least three independent experiments.
Quantification of histological score (h). *p < 0.01, versus sham group;
°p < 0.01, versus MCAo+ vehicle group. ND: not detectable
Fig. 1 Regional cerebral blood
flow analysis (rCBF). rCBF was
monitored 10 min before
ischemia (baseline); at 10, 60, and
110 min during ischemia; and
5 min after ischemia. rCBF
monitoring was used to confirm
successful induction of MCAo
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partial neuronal cell loss only and the presence of intact
neurons between the vacuolated spaces (Fig. 2e (E1);
see histological score H). Hippocampal CA1 pyramidal
cells 24 h after reperfusion were layered and arranged
uniformly with large, round, transparent, and intact nu-
clei (data not shown). In the ischemia/reperfusion group,
CA1 neurons were significantly reduced in numbers and
characterized by pyknotic and indistinct nuclei (Fig. 2f
(F1); see histological score H). Co-ultraPEALut treat-
ment significantly decreased neuronal cell death in
CA1 (Fig. 2g (G1); see histological score H).
Effect of Co-ultraPEALut on Astrocyte Activation After
MCAo
Astrocytes were revealed by GFAP immunohistochemis-
try; active astrocytes were defined as GFAP-stained cells
with an increased GFAP immunoreactivity. A basal
number of astrocytes were detected in the sham controls
(Fig. 3b). Twenty-two hours of ischemia/reperfusion
resulted in significant increases in the number of astro-
cytes and GFAP immunoreactivity in the cortical IBZ
and RZ when compared to the sham control or contra-
lateral hemisphere (Fig. 3b, c). GFAP-positive astrocytes
were more numerous in the border zone compared to
the remote zone (Fig. 3b). The number of GFAP-
stained cells in the contralateral hemisphere was similar
to the sham control (Fig. 3c). Brain sections from sham-
operated rats did not exhibit appreciable immunostaining
for GFAP (data not shown), unlike infarct border zone
sections from MCAo rats (Fig. 3c). Co-ultraPEALut re-
duced GFAP immunostaining in the infarct border zone
of rats subjected to MCAo (Fig. 3d). Western blot anal-
ysis confirmed the immunohistochemical findings, with
a low level of GFAP expression in extracts from the
occluded hemisphere of sham-operated rats and a signif-
icant increase in the MCAo vehicle-treated group
(Fig. 3e (E1)). Co-ultraPEALut decreased the damage-
induced rise in GFAP expression to a significant extent
(Fig. 3d (D1)).
Fig. 3 Co-ultraPEALut moderates MCAo-induced activation of
astrocytes. A representative brain section showing the regions of
interest used for analysis: cortical infarct border zone (IBZ), ipsilateral
cortical remote zone (RZ), and contralateral hemisphere (CH) (a). The
number of glial fibrillary acidic protein (GFAP)-positive cells was
counted in three sections per animal in each experimental region and
presented as the number of positive cells per high-power field (b).
Immunohistochemical localization of GFAP shows positive staining in
the IBZ of vehicle-treated MCAo animals (c) in contrast to the co-
ultraPEALut-treated ischemic rats (d). Western blot analysis
demonstrated a marked increase in GFAP-immunoreactive protein in
ischemic tissue and its moderation by co-ultraPEALut treatment (e, E1).
Values in E1 aremean± SD for five to six rats from each group. *p < 0.01,
versus sham group; #p < 0.01, versus MCAo group. Data are
representative of three independent experiments
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Co-ultraPEALut Limits Ischemia-Induced Loss of BDNF
and GDNF Expression
Brain tissues from MCAo rats showed a marked reduction in
the levels of the neurotrophic factors BDNF and GDNF, as
determined by Western blot 24 h post-ischemia (Fig. 4a (A1),
b (B1)). Treatment with co-ultraPEALut increased the expres-
sion levels of both BDNF and GDNF in comparison to with
non-treated injured rats.
Co-ultraPEALut Reduces Ischemia-Induced Mast Cell
Infiltration and Chymase and Tryptase Expression
Toluidine blue staining of the brain tissue fromMCAo vehicle-
treated rats identified cells with metachromatic granules, a char-
acteristic of mast cells (Fig. 5a, c). In contrast, significantly
fewer cells of this type were seen in the ischemic tissue of rats
treated with co-ultraPEALut (Fig. 5b, c) and none in sham-
operated rats (data not shown). While immunoreactivity for
chymase and tryptase, two serine peptidases characteristic of
mast cells, was absent in brain tissues from sham-operated rats
(data not shown), there were substantial increases 24 h after
ischemia (Fig. 5d, g, respectively, see densitometries F and I).
Chymase and tryptase expression was attenuated in tissue sec-
tions from rats receiving co-ultraPEALut (Fig. 5e, h, respec-
tively, see densitometries F and I).
Co-ultraPEALut Effect on Bax and Bcl-2 Expression
Western blot analysis was employed to determine the levels of
Bax and Bcl-2 expression. As shown in Fig. 6, co-
ultraPEALut administration effectively normalized the Bax
level in the brain of rats subjected to MCAo (Fig. 6b). At
the same time, co-ultraPEALut significantly restored the re-
duction in Bcl-2 expression observed in MCAo rats (Fig. 6c).
As such, co-ultraPEALut administration normalized the Bax/
Bcl-2 expression level (Fig. 6d).
Clinical Assessment of Stroke Patients Treated
with Glialia®
Nine of the 250 enrolled patients dropped out because of death
owing to severity of concomitant diseases or seriousness of
ischemic state (2), transfer to another rehabilitation center (3),
onset of diarrhea (2), gastric discomfort (1), and agitation (1).
None of these reasons were considered by the attending phy-
sician to be treatment related. The CNS showed a significant
improvement over time (p<0.0001), with the mean total score
increasing by 1.7±0.10 between T0 and T30 (Fig. 7). Further-
more, GLMM analysis showed that while baseline average
score in women was indicative of greater severity than males
(p=0.0049), improvement over time was independent of both
gender and recovery type.
Fig. 4 Co-ultraPEALut restores the MCAo-induced loss of BDNF and
GDNF expression. Co-ultraPEALut (1 mg/kg) was administered orally
1 h after ischemia and 6 h post-reperfusion. Animals were sacrificed 24 h
after MCAo, and brain tissue lysates were analyzed by Western blot for
BDNF and GDNF. Ischemic rats exhibited a marked reduction in the
levels of both BDNF (a, A1) and GDNF (b, B1) which were restored
by co-ultraPEALut treatment. Data are mean ± SD for five to six rats
from each group. *p < 0.01, versus sham group; **p < 0.001, versus
sham group; #p < 0.01, versus MCAo group. Representative blots are
shown in a, b, with quantification of all animals given in A1, B1
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Cognitive function evaluation performed by MMSE
showed a significant improvement (p < 0.0001) com-
pared to baseline performance after 30 days of
Glialia® treatment (Fig. 7). The average score over
these 30 days of treatment increased from 20.2 ± 0.57
(T0) to 22.7 ± 0.47 (T30). Out of the 78 patients who
were unable to perform the MMSE at baseline, 28 were
capable of carrying out the test at follow-up after
30 days of treatment. The MMSE analysis showed also
that at baseline, female patients had a significantly
(p= 0.0450) greater cognitive impairment compared to
males. However, there was no time × recovery and gen-
der effect.
Muscle spasticity evaluated by the Ashworth Scale showed
that the global spasticity significantly improved over time
(p<0.0015) (Fig. 7). The severity of spasticity at baseline
was greater in outpatients (p<0.0003) than in inpatients, and
outpatient improvement was statistically significantly greater
(p<0.0075) than that of inpatients. These observations apply
to the assessment of spasticity both overall and at the level of
each limb.
The average pain intensity detected by NRS fell
within a range of values considered clinically very
mild. The average value for NRS at baseline was 2.1
± 0.17; after 30 days of Glialia® treatment, this had
decreased one point to a mean value of 1.1 ± 0.11
(p < 0.0001) (Fig. 7). The baseline mean score of pain
intensity appeared higher in outpatients (3.1 ± 0.49)
compared to inpatients (1.9 ± 0.18) and reached a sta-
tistical significance (p = 0.0014).
Fig. 5 Effect of co-ultraPEALut treatment on mast cells in MCAo rats.
Co-ultraPEALut (1mg/kg) was administered orally 1 h after ischemia and
6 h post-reperfusion. Animals were sacrificed 24 h after MCAo, and
tissues were prepared for immunohistochemical analysis. (a) Toluidine
blue-stained mast cells with their characteristic metachromatic granular
inclusions were evident in MCAo-vehicle treated rats. (b) Co-
ultraPEALut-treated ischemic animals displayed only occasional cells
of this type. (c) Mast cell density per unit area. A marked increase in
immunoreactivity for the mast cell enzymes chymase (d) and tryptase
(g) was seen in the brain sections from MCAo vehicle-treated rats. This
expression was significantly attenuated in the MCAo group treated with
co-ultraPEALut (e, h). Densitometric analysis for chymase (f) and
tryptase (i) immunoreactivities is given (five photomicrographs from
each sample collected from all rats in each experimental group) and
was carried out using Optilab Graftek software on a Macintosh personal
computer (CPU G3-266). Data, expressed as percentage of total tissue
area, are mean ± SD. *p < 0.01, versus sham group; °p < 0.01, versus
MCAo+ vehicle group. ND not detectable
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Patients’ independence and mobility in daily living activi-
ties (Barthel Index) showed a significant improvement
(p<0.0001) after 30 and 60 days of treatment (mean scores
of 26.6 ±1.69, 48.3± 1.91, and 60.5±1.95 at T0, T30, and
T60, respectively) (Fig. 8). Moreover, there was a highly sig-
nificant difference between T30 and T60, indicative of a con-
tinuing improvement with time. The baseline degree of dis-
ability in daily living activity was significantly more severe in
inpatients (p < 0.0003) than outpatients and in females
(p< 0.0047) compared to males; improvement over time,
however, appeared better in inpatients and was not influenced
by gender.
Tolerability to Glialia® treatment was excellent, with no
adverse events ever having been observed over the course of
this study. Further, routine blood chemistry and hematology
analyses did not reveal any deviations from their normal
ranges in relation to Glialia® treatment.
Discussion
Cerebral ischemia continues to represent one of the principal
unmet medical needs in today’s society. Stroke is especially
devastating, given that it constitutes themost frequent cause of
neurological disability worldwide. The underlying cellular
mechanisms of stroke neuropathology are complex. An initial
episode of focal hypoperfusion subsequently leads to
excitotoxicity, oxidative damage, microvascular injury,
blood–brain barrier dysfunction, and post-ischemic inflamma-
tion [4, 49–51]. Despite almost four decades of experimental
animal investigations on stroke and the identification of a
spectrum of anti-inflammatory/neuroprotective compounds
[11–15], translatability of these findings to human clinical
trials until now have been proven uniformly disappointing
[3, 16]. In the present study, we describe the neuroprotective
effects of co-ultramicronized palmitoylethanolamide/luteolin
Fig. 6 Effects of co-ultraPEALut on Bax and Bcl-2. Co-ultraPEALut
(1 mg/kg) was administered orally 1 h after ischemia and 6 h post-
reperfusion. Animals were sacrificed 24 h after MCAo, and brain tissue
lysates were analyzed by Western blot for Bax and Bcl-2. (a, b) Co-
ultraPEALut treatment reduced the levels of Bax in the brain of
ischemic rats. β-Actin was used as internal control. (a, c) Co-
ultraPEALut administration increased the Bcl-2 levels in the brain
tissue of ischemic rats. Co-ultraPEALut administration normalized Bax/
Bcl-2 expression levels (d). Data are mean ± SD for five to six rats from
each group. *p < 0.01, versus sham group; **p < 0.001, versus sham
group; ###p < 0.001; #p < 0.01, versus MCAo group. Representative
blots are shown in a, with quantification of all animals given in b–d
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in a rat model of focal cerebral ischemia and, more important-
ly, the ability of co-ultraPEALut (Glialia®) to improve the
neurological status of stroke patients undergoing
neurorehabilitation.
Focal cerebral ischemia is accompanied by reactive
astrogliosis [52] and activation of microglial cells in the hip-
pocampal area [53]. Reactive gliosis can lead to the produc-
tion of excessive amounts of cytokines as well as inflamma-
tory products that exacerbate ischemic damage [54]. In our
study, an increased in GFAP immunoreactivity was observed
in the MCAo group in comparison to sham-operated animals
while there was a marked reduction in the co-ultraPEALut-
treated group. As previously reported [55], co-ultraPEALut is
able to significantly reduce expression levels of GFAP after
MCAo. In the current MCAo model, oral administration of
co-ultraPEALut 1 h after ischemia and 6 h after reperfusion
improved neurological score, reduced lesion size and histo-
logical damage, inhibited mast cell infiltration/degranulation
and astrocyte activation (as measured by GFAP accumulation,
a characteristic neuropathologic feature of ischemic brain in-
jury [56]), and restored expression of BDNF and GDNF. Ex-
perimental and clinical studies have shown that BDNF and
GDNF are upregulated at very early stages during brain ische-
mia [56]. Furthermore, exogenous administration of GDNF
and BDNF reduced the toxic effects of excitatory amino acids,
attenuated nitric oxide production, and lowered apoptosis/cell
death in stroke animal models [56, 57]. In our preclinical
findings, protein analysis showed that both BDNF and GFAP
Fig. 7 Neurological scoring for stroke patients treated with Glialia®.
Patients were administered Glialia®, as described in the BMaterials and
Methods^ section, for a period of 60 days and underwent the following
evaluations at baseline (T0) and after 30 days (T30). Canadian
Neurological Score values were 6.4 ± 0.16 and 8.1 ± 0.15 at T0 (242
patients) and T30 (237 patients), respectively. Delta: T30–T0 was
calculated on the basis of 237 patients. There was a significant
difference in time (***p < 0.0001) between T0 and T30. Mini Mental
State Exam values were 20.2 ± 0.57 and 22.7 ± 0.47 at T0 (169 patients)
and T30 (196 patients), respectively. Delta: T30–T0was calculated on the
basis of 167 patients. There were significant differences in time
(***p < 0.0001) between T0 and T30. Seventy-two patients were
unable to carry out the exam at T0; 28 of these were able to take the
test at T30. Ashworth Scale values were 4.1 ± 0.32 and 3.7 ± 0.27 at T0
(246 patients) and T30 (244 patients), respectively. Delta: T30–T0 was
calculated on the basis of 244 patients. There was a significant difference
in time (**p < 0.0015) between T0 and T30. Numerical Rating Scale
values were 2.1 ± 0.17 and 1.1 ± 0.11 at T0 (242 patients) and T30 (241
patients), respectively. Delta: T30–T0 was calculated on the basis of 241
patients. There was a significant difference in time (***p< 0.0001)
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levels were downregulated by cerebral ischemia while a local
and sustained increase in their expression in the perilesioned
tissue followed oral administration of co-ultraPEALut.
Mast cell activation and degranulation is known to contrib-
ute to blood–brain barrier disruption in cerebral ischemia [58].
Other elements play a role in ischemic brain damage, such as
activation of the transcription factor nuclear factor-κB [59,
60], inducible nitric oxide synthase [61, 62], and poly(ADP-
ribose)synthetase [63]; increased expression of the pro-
apoptotic protein Bax [64]; and decreased expression of the
anti-apoptotic molecule Bcl-2 [65]. In the present study, co-
ultraPEALut significantly reduced nuclear factor-κB translo-
cation, attenuated poly(ADP-ribose)synthetase activation, and
normalized Bax/Bcl-2 expression levels. These results are
qualitatively similar to our earlier investigations with PEA
alone, although in the latter, 10-fold higher doses of PEA
(compared to co-ultraPEALut) were required for efficacy
[55, 66].
PEA actions are mediated, at least in part, by activation of
peroxisome proliferator-activated receptors, accompanied by
a decrease in neutrophil influx and expression of pro-
inflammatory proteins, such as inducible nitric oxide synthase
and cyclooxygenase-2 [39, 67]. Luteolin displays specific
anti-inflammatory effects, which are only partly explained
by its antioxidant capacities. The anti-inflammatory activity
of luteolin includes activation of antioxidative enzymes, sup-
pression of the nuclear factor-κB pathway, and inhibition of
pro-inflammatory substances [68, 69]. The molecular basis
behind the superior pharmacological efficacy of co-
ultraPEALut compared to comparable concentrations of the
single chemical components is currently under investigation.
Although inflammatory signaling is considered to partici-
pate in the early post-ischemic period, as the ischemic cascade
progresses, cell death leads to a new phase of the inflamma-
tory response, whereby the immune system becomes activat-
ed. There is evidence that both microglia and mast cells have a
role at later times following the ischemic episode. Mast cells
possess a potent armamentarium to target the components of
the blood–brain barrier and basal lamina shortly after their
activation in ischemia, whereas de novo production of medi-
ators reactivates and maintains the process over the longer
term [70–73]. Further, a newly published study demonstrates
that mast cells can undergo a delayed and long-term activation
following traumatic brain injury [74]. While the latter condi-
tion is not stroke, this report demonstrates that mast cells are
not only early responders but also long-term players in brain
injury. Further, it bears keeping in mind that in terms of acute
versus late-stage treatment regimens in rats and man, one
cannot necessarily make a direct comparison between time
scales. In other words, a patient treated starting 60 days
post-stroke does not have a rat equivalent.
Despite literally hundreds of compounds and interventions
that provide benefit in experimental models of cerebral ische-
mia, efficacy in humans remains to be demonstrated [75].
Many patients with ischemic stroke, despite optimal medical
treatment received during the acute phase, often fail to recover
(or only partially), leading to persistent disability requiring
Fig. 8 Barthel Index score for stroke patients treated with Glialia®.
Patients were administered Glialia®, as described in the BMaterials and
Methods^ section, for a period of 60 days. Barthel Index values were
26.6 ± 1.69, 48.3 ± 1.91, and 60.5 ± 1.95 at T0 (242 patients), T30 (229
patients), and T60 (218 patients), respectively. There was a significant
difference in the improvement between T0 and T30 (***p < 0.0001) and
between T0 and T60 (###p < 0.0001). Moreover, there was a highly
significant difference also between T30 and T60 (p< 0.0001). Female
patients exhibited lower scores than males, and disability was worse in
inpatients
Table 5 Comparison of current
multicenter study results with
reported values for stroke patients
not receiving Glialia®
Multicenter study Study Aa Study Bb
Δc Δc Δc
Canadian Neurological Scale 1.80 0.01 (p < 0.0001) 1.02 (p < 0.0001)
Ashworth Scale −0.20 – 0.58 (p < 0.0009)
Barthel Index 36.2 0.62 (p < 0.0001) 34.8 n.s.
a Fornasari et al. [77]
b Current data (C. Cisari)
c The mean value achieved between basal and study end
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rehabilitation. As Glialia® is already a marketed product, we
investigated whether treatment with Glialia®, carried out si-
multaneously with rehabilitation therapy, can bring about a
better functional recovery in stroke patients in the subacute
phase. The observations reported here demonstrate that a pos-
itive outcome in an animal stroke model can be translated into
stroke patients. Open studies, however, necessarily impose
certain limitations as, for example, the lack of a randomized
controlled trial’s robustness and the absence of a control
group. Further, outcome of an observational study may be
biased by patient attributes that affect treatment selection. For-
mal clinical trials typically employ randomization to address
some of these issues by balancing baseline characteristics
among the treatment groups. This open study was intended
to consider patients who are observed in the context of neu-
rological disability resulting from cerebral ischemia and un-
dergoing rehabilitation—independent of their gravity. The
large patient base provided a range in times from initial ische-
mic episode until the beginning of treatment with Glialia® and
can serve to gauge the evolution of a patient’s disability with
treatment in a long-term rehabilitation setting with the same
rehabilitation team. We believe that such information may
allow one to derive considerations for clinical practice on
choice of therapy to combine with rehabilitation for patients
with persistent stroke-related neurological disabilities.
Systematic reviews comparing the results of randomized
controlled trials and observational studies of the same agents
have failed to demonstrate significant differences in outcomes
across multiple study designs [76]. In order to address the
absence of a control patient group, we compared the results
obtained by the CNS, Ashworth Scale, and Barthel Index in
patients treated with Glialia® with historical literature [77]
data observed in patients having similar pathologic conditions
but never receiving Glialia® (Table 5). A z test comparing the
mean value reported (standard error was not given) and that of
the present study was performed; this comparison is limited to
the observed mean value and a fixed value. As such, the test
tends to overestimate the probability value and therefore was
fixed (alpha=0.01).
These caveats aside, this represents the first descrip-
tion of co-ultraPEALut administration to human stroke
patients and clinical improvement not otherwise expect-
ed from spontaneous recovery. Based on these observa-
tions, we believe that controlled trials are warranted to
confirm the utility of co-ultraPEALut to improve clini-
cal outcome in human stroke, also in consideration of
the excellent tolerability associated with Glialia® treat-
ment. A double-blind, randomized, and placebo-
controlled trial of Glialia® in stroke patients within
12 h of the initial ischemic episode has been initiated.
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